Humanized Monoclonal Antibody OMP22 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Acinetobacter baumannii, a multi-drug resistant bacterial pathogen, face challenges such as cross-reactivity with other Gram-negative bacteria, limiting the effectiveness of polyclonal antibodies in detection and requiring complex, costly, and time-consuming procedures.
Innovation Solution
Development of a polyclonal antibody (AB-pAb) specifically targeting the conserved 22 kDa outer membrane protein (OMP22) of Acinetobacter baumannii, optimized to reduce cross-reactivity with other Gram-negative bacteria, allowing for efficient detection in clinical samples like blood and urine using simplified antibody-based diagnostic tests.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polyclonal antibodies are used for detecting Acinetobacter baumannii, then detection coverage is improved, but cross-reactivity with other Gram-negative bacteria increases
Solution Approach 1:
The patent segments the detection approach by using a combination of multiple monoclonal antibodies (each targeting different epitopes of OMP22) to achieve the detection coverage previously provided by polyclonal antibodies, while eliminating cross-reactivity through highly specific antigen recognition
Solution Approach 2:
The patent changes the specificity parameter of the antibody by using genetically engineered humanized monoclonal antibodies with optimized variable regions (VH and VL domains) that maintain high affinity for A. baumannii OMP22 while reducing cross-reactivity with other Gram-negative bacteria
2Object-affected harmful factors
If traditional diagnostic methods are used, then cross-reactivity is reduced, but diagnostic complexity and cost increase
Solution Approach 1:
The patent uses a genetically engineered humanized monoclonal antibody as an intermediary that provides high-specificity binding to A. baumannii OMP22, enabling simple immunoassay-based diagnostics without the complexity of traditional methods while maintaining low cross-reactivity
Solution Approach 2:
The patent replaces complex mechanical/biochemical diagnostic systems with a simplified immunological detection system based on highly specific monoclonal antibody-antigen binding, reducing diagnostic complexity while improving specificity
3Measurement precision
If polyclonal antibodies are used for detection, then sensitivity is improved, but diagnostic time and resource requirements increase
Solution Approach 1:
The patent uses engineered monoclonal antibodies that self-assemble into functional detection reagents with optimized binding kinetics, eliminating the need for complex antibody preparation and purification steps required by polyclonal antibodies, thus reducing diagnostic time while maintaining sensitivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AB-pAb demonstrates high sensitivity (85.5%) and specificity (99.5%) in recognizing A. baumannii, offering a rapid, cost-effective, and simple diagnostic solution for detecting the pathogen, particularly in healthcare settings.
Implementation Method 1
The AB-pAb specifically binds to antigen(s) from Acinetobacter baumannii (A. baumannii), wherein the polyclonal antibody shows limited cross-reactivity to antigens from other gram-negative bacteria
Data Source
AI summary
The disclosure provides for a polyclonal antibody that specifically detects Acinetobacter baumannii, a multi-drug resistant (MDR) bacterial pathogen, and uses thereof, including as diagnostic tests and for immunoassays to be used in therapeutic decision-making or research experiments.